Table 2 Drug and device treatment of surviving patients by screening arm at baseline and after 12 months of follow-up
Medical therapy | Echocardiography screening (n = 600) | No echocardiography screening (n = 601) | ||
|---|---|---|---|---|
Baseline (n = 600) | Follow-up (n = 468) | Baseline (n = 601) | Follow-up (n = 435) | |
β-Blocker, n (%) | 263 (44) | 248 (53) | 264 (44) | 210 (49) |
ACEi or ARB, n (%) | 297 (50) | 256 (54) | 301 (50) | 213 (49) |
Loop diuretic, n (%) | 136 (23) | 118 (25) | 125 (21) | 29 (18,) |
MRA, n (%) | 97 (16) | 25 (5) | 99 (16) | 11 (2.5) |
Statin, n (%) | 308 (51) | 239 (51) | 300 (50) | 205 (47) |
Anti-platelet, n (%) | 199 (33) | 127 (27) | 202 (34) | 125 (29) |
Anticoagulation, n (%) | 210 (35) | 185 (43) | 203 (34) | 148 (34) |
Digoxin, n (%) | 48 (8) | 37 (8) | 38 (6) | 30 (7) |
CRT upgrade, n (%) | 0 (0) | 7 (1.2) | 0 () | 4 (0.6) |
